Vanguard Global Advisers
LGND icon

Vanguard Global Advisers’s Ligand Pharmaceuticals LGND Stock Holding History

Vanguard Global Advisers’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.6M Sell
8,228
-74
-0.9% -$17.4K ﹤0.01% 1101
2026
Q1 		$1.66M Buy
+8,302
New +$1.64M ﹤0.01% 1321

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Global Advisers's LGND Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Ligand Pharmaceuticals (LGND) stake by 0.89% in Q2 2026, selling an estimated $17.4K and leaving 8,228 shares worth $2.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1101.

Vanguard Global Advisers first reported a position in LGND in Q1 2026 and has held it in 2 quarters since. 410 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Vanguard Global Advisers held 8,228 shares of Ligand Pharmaceuticals worth $2.6M as of Q2 2026.
  • Vanguard Global Advisers sold 74 Ligand Pharmaceuticals shares in Q2 2026, an estimated $17.4K.
  • Ligand Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1101 holding.
  • Vanguard Global Advisers first reported a position in Ligand Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 410 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.